|
|
Phase III Randomized Study of Paclitaxel With or Without Bevacizumab in Patients With Locally Recurrent or Metastatic Breast Cancer
Alternate Title Basic Trial Information Objectives Entry Criteria Expected Enrollment Outline Published Results Related Publications Trial Contact Information Registry Information
Alternate Title
Paclitaxel With or Without Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast Cancer
Basic Trial Information
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase III
|
|
|
|
Treatment
|
|
|
|
Closed
|
|
|
|
18 and over
|
|
|
|
NCI
|
|
|
|
ECOG-2100 NCCTG-E2100, CAN-NCIC-MAC3, NSABP-E2100, E2100, NCT00028990, MAC3
|
|
|
Special Category:
CTSU trial Objectives - Compare the time to treatment failure in patients with locally recurrent or metastatic breast cancer treated with paclitaxel with or without bevacizumab.
- Compare the objective response rate, duration of response, overall survival, and time to progression in patients treated with these regimens.
- Compare the toxicity of these regimens in these patients.
- Compare the quality of life of patients treated with these regimens.
Entry Criteria Disease Characteristics:
- Histologically or cytologically confirmed adenocarcinoma of the breast
- Locally recurrent disease that is not amenable to surgical resection with
curative intent
OR
- Metastatic disease
- No HER-2-overexpressing (3+) breast cancer unless previously treated with
trastuzumab (Herceptin)
- Unknown HER-2 status allowed provided herceptin-based
therapy inappropriate
or not indicated
- No prior or radiologic evidence of CNS metastases, including previously
treated, resected, or asymptomatic brain lesions or leptomeningeal
involvement
by head CT scan or MRI
- Hormone receptor status:
Prior/Concurrent Therapy:
Biologic therapy: - See Disease Characteristics
Chemotherapy: - No prior chemotherapy for locally recurrent or metastatic
breast cancer
- At least 12 months since prior adjuvant or neoadjuvant taxane
therapy
- At least 3 weeks since prior adjuvant chemotherapy
Endocrine therapy: - At least 3 weeks since prior hormonal therapy for locally
recurrent or metastatic breast cancer
Radiotherapy: - At least 3 weeks since prior radiotherapy
- No prior radiotherapy to only site of disease
- No concurrent local radiotherapy for pain control or
life-threatening situations (e.g, superior vena cava syndrome, spinal cord
compression, or CNS metastases)
Surgery: - At least 4 weeks since prior major surgical procedure except
placement of vascular access device or breast biopsy
- At least 7 days since prior minor surgical procedure,
including placement of an access device or fine needle aspiration
Other: - At least 10 days since prior anticoagulant therapy (low-dose
anticoagulant therapy to maintain patency of a vascular access device
allowed)
- At least 10 days since prior and no concurrent daily aspirin
(more than 325 mg/day) or other non-steroidal anti-inflammatory medication
known to inhibit platelet function
- No concurrent dipyridamole, ticlopidine, clopidogrel, or
cilostazol
Patient Characteristics:
Age: Sex: Menopausal status: Performance status: Life expectancy: Hematopoietic: - Absolute neutrophil count at least 1,500/mm3
- Platelet count at least 100,000/mm3
- No prior bleeding diathesis
Hepatic: - Bilirubin no greater than 1.5 mg/dL
- SGOT no greater than 2 times upper limit of normal (ULN) (5
times ULN for known liver involvement)
- PT/PTT no greater than 1.5 times normal
- INR no greater than 1.5 times normal
Renal: - Creatinine no greater than 2.0 mg/dL
- No proteinuria by dipstick urinalysis
- Trace proteinuria allowed
- Proteinuria less than 500 mg by 24-hour urine collection if
proteinuria at least 1+ by urinalysis
Cardiovascular: - No clinically significant cardiovascular disease
- No myocardial infarction within the past 12 months
- No unstable angina
- No prior deep vein thrombosis
- No grade 2 or greater peripheral vascular disease
- No uncontrolled congestive heart failure
- No uncontrolled hypertension (systolic blood pressure greater
than 170 mmHg and diastolic blood pressure greater than 95 mm Hg)
- No prior cerebrovascular accident
Pulmonary: - No prior pulmonary embolism
Other: - Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective non-hormonal
contraception
- No history of seizures
- No non-healing wound or fracture
- No hypersensitivity to paclitaxel, Cremophor EL, Chinese
hamster ovary cell products, or other recombinant human antibodies
- No active infection requiring parenteral antibiotics
Expected Enrollment A total of 316-650 patients (158-325 per treatment arm) will be accrued for
this study within 31 months. Outline This is a randomized, open-label, multicenter study. Patients are
stratified according to disease-free interval (no more than 24 months vs more
than 24 months), number of metastatic sites (less than 3 vs 3 or more),
treatment with prior adjuvant chemotherapy (yes vs no), and estrogen receptor
status (positive vs negative vs unknown). Patients are randomized to one of
two treatment arms. - Arm I: Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15
followed by bevacizumab IV over 30-90 minutes on days 1 and 15.
- Arm II: Patients receive paclitaxel as in arm I.
In both arms, courses repeat every 4 weeks in the
absence of disease progression or unacceptable toxicity. Quality of life is assessed at baseline and on day 1 of weeks 17 and
33. Patients are followed every 3 months for 2 years, every 6 months for 3
years, and then annually thereafter. Published ResultsSchneider BP, Wang M, Radovich M, et al.: Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 26 (28): 4672-8, 2008.[PUBMED Abstract] Miller K, Wang M, Gralow J, et al.: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357 (26): 2666-76, 2007.[PUBMED Abstract] Wagner LI, Wang M, Miller K, et al.: Health-related quality of life among patients with metastatic breast cancer receiving paclitaxel versus paclitaxel plus bevacizumab: results from the Eastern Cooperative Oncology Group (ECOG) study E2100. [Abstract] Breast Cancer Res Treat 100 (Suppl 1): A-5078, S239, 2006. Miller KD, Wang M, Gralow J, et al.: A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group (E2100). [Abstract] Breast Cancer Research and Treatment 94 (Suppl 1): A-3, 2005. Miller KD: E2100: a phase III trial of paclitaxel versus paclitaxel/bevacizumab for metastatic breast cancer. Clin Breast Cancer 3 (6): 421-2, 2003.[PUBMED Abstract] Related PublicationsGray R, Giantonio BJ, O'Dwyer PJ, et al.: The safety of adding angiogenesis inhibition into treatment for colorectal, breast, and lung cancer: the Eastern Cooperative Oncology Group's (ECOG) experience with bevacizumab (anti-VEGF). [Abstract] Proceedings of the American Society of Clinical Oncology 22: A-825, 2003.
Trial Contact Information
Trial Lead Organizations Eastern Cooperative Oncology Group | | | Kathy Miller, MD, Protocol chair | | | | Robin Zon, MD, Protocol co-chair | | | |
North Central Cancer Treatment Group | | | Edith Perez, MD, Protocol chair | | | |
NCIC-Clinical Trials Group | | | Tamara Shenkier, MD, Protocol chair | | | |
National Surgical Adjuvant Breast and Bowel Project | | | Melody Cobleigh, MD, Protocol chair | | | |
Registry Information | | Official Title | | A Randomized Phase III Tial Of Paclitaxel Versus Paclitaxel Plus Bevacizumab (rhuMAb VEGF) As First-Line Therapy For Locally Recurrent or Metastatic Breast Cancer | | Trial Start Date | | 2001-12-21 | | Registered in ClinicalTrials.gov | | NCT00028990 | | Date Submitted to PDQ | | 2001-11-21 | | Information Last Verified | | 2006-07-27 | | NCI Grant/Contract Number | | CA21115 |
Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol. Back to Top |
|